Chapter title |
Iron Deficiency Treatment in Patients with Heart Failure
|
---|---|
Chapter number | 30 |
Book title |
Heart Failure
|
Published in |
Handbook of experimental pharmacology, January 2017
|
DOI | 10.1007/164_2017_30 |
Pubmed ID | |
Book ISBNs |
978-3-31-959658-7, 978-3-31-959659-4
|
Authors |
Ewa A. Jankowska, Marcin Drozd, Piotr Ponikowski |
Abstract |
Iron deficiency (ID) is one of the major risk factors for disability and mortality worldwide, and it was identified as a common and ominous comorbidity in patients with heart failure (HF), both with and without anaemia. Based on two clinical trials (FAIR-HF and CONFIRM-HF) and other epidemiological evidence, ID has been recognized as an important therapeutic target in symptomatic patients with HF and LVEF ≤45%.Intravenous iron supplementation has been demonstrated to be safe and effective for iron repletion and related with an improvement in clinical status, exercise capacity, and quality of life. Ongoing trials are testing the hypothesis that such a therapy may also reduce the risk of HF hospitalizations and cardiovascular death. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 38 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 16% |
Unspecified | 5 | 13% |
Professor | 4 | 11% |
Student > Postgraduate | 3 | 8% |
Researcher | 3 | 8% |
Other | 8 | 21% |
Unknown | 9 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 45% |
Unspecified | 5 | 13% |
Nursing and Health Professions | 1 | 3% |
Sports and Recreations | 1 | 3% |
Economics, Econometrics and Finance | 1 | 3% |
Other | 2 | 5% |
Unknown | 11 | 29% |